Abeona Therapeutics (NASDAQ:ABEO) CFO Joseph Walter Vazzano Sells 9,035 Shares of Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) CFO Joseph Walter Vazzano sold 9,035 shares of the stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $5.39, for a total transaction of $48,698.65. Following the completion of the transaction, the chief financial officer owned 453,631 shares in the company, valued at $2,445,071.09. This trade represents a 1.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Joseph Walter Vazzano also recently made the following trade(s):

• On Tuesday, July 22nd, Joseph Walter Vazzano sold 1,502 shares of Abeona Therapeutics stock. The shares were sold at an average price of $6.64, for a total transaction of $9,973.28.
• On Wednesday, July 9th, Joseph Walter Vazzano sold 25,411 shares of Abeona Therapeutics stock. The stock was sold at an average price of $5.86, for a total transaction of $148,908.46.

Abeona Therapeutics Stock Performance

Shares of Abeona Therapeutics stock opened at $5.28 on Thursday. Abeona Therapeutics Inc. has a 1-year low of $3.93 and a 1-year high of $7.54. The company’s fifty day simple moving average is $6.41 and its 200-day simple moving average is $5.92. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.73 and a quick ratio of 6.65. The stock has a market capitalization of $270.76 million, a PE ratio of 7.54 and a beta of 1.43.

Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Thursday, August 14th. The biopharmaceutical company reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $2.10. The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $21.71 million. As a group, equities analysts anticipate that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ABEO has been the topic of a number of analyst reports. Oppenheimer lifted their price objective on Abeona Therapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a research report on Friday, August 15th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Abeona Therapeutics in a research report on Monday, August 18th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $19.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ABEO. Ameritas Investment Partners Inc. bought a new stake in shares of Abeona Therapeutics during the second quarter valued at approximately $25,000. Legal & General Group Plc bought a new position in shares of Abeona Therapeutics during the second quarter worth $27,000. Riverwater Partners LLC purchased a new position in Abeona Therapeutics during the second quarter valued at $62,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Abeona Therapeutics during the second quarter valued at $63,000. Finally, Man Group plc bought a new stake in Abeona Therapeutics in the 2nd quarter valued at $67,000. 80.56% of the stock is currently owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.